// App-Quantinova.ai

138 : AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Emmanuel S. Antonarakis

Principal Investigators

  • Changxue Lu

  • Yan Chen

  • Michael Anthony Carducci

  • Mario A. Eisenberger

  • Mary Nakazawa

  • Angelo M. De Marzo

  • William B. Isaacs

  • Rosa Nadal

  • Channing Judith Paller

  • Samuel R. Denmeade

  • Jun Luo

  • Brandon Luber

  • Hao Wang

Medical Centers

  • The Johns Hopkins Medical Institutions, Baltimore, MD

  • The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MDThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • Cabazitaxel

  • Docetaxel

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved